Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

A Prospective, Multicenter, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of Moxibustion in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

A total of 42 patients with SR-aGVHD, primarily involving the gastrointestinal tract and presenting with abdominal pain and diarrhea, will be enrolled. All participants will receive standard second-line therapy based on best available treatment (BAT), including ruxolitinib, basiliximab, or methotrexate, according to clinical judgment. In addition, patients will receive moxibustion at specific acupoints (Tianshu [ST25], Shenque [CV8], and Qihai [CV6]) for 30 minutes once or twice daily for 28 days.

The primary endpoint is the overall response rate (ORR) at Day 28. Secondary endpoints include durable ORR at Day 56, incidence and severity of chronic GVHD (cGVHD), non-relapse mortality (NRM), overall survival (OS), and changes in traditional Chinese medicine (TCM) syndrome scores. Safety will be assessed by monitoring adverse events throughout the study period.

This study aims to explore whether moxibustion, as an adjunctive therapy, can improve clinical outcomes and provide a safe and effective treatment strategy for patients with SR-aGVHD after allo-HSCT.

Study Overview

• Status: Recruiting
• Conditions: Allogeneic Hematopoietic Stem Cell Transplantation; Graft-Versus-Host Disease; Acute Graft-Versus-Host Disease; Steroid-Refractory Acute Graft-Versus-Host Disease
• Intervention / Treatment: Procedure: Moxibustion; Procedure: Moxibustion Twice Daily Plus Best Available Treatment (BID Group); Drug: Best Available Treatment (BAT)

• Study Type: Interventional
• Enrollment (Estimated): 42
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: wei MD, PhD; Phone Number: +86 027-85726003; Email: shiwei076@hust.edu.cn

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430022
      • Recruiting
      • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Contact: Wei Shi, M.D.; Phone Number: +86 027-85726003; Email: shiwei076@hust.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants must meet all of the following criteria:

Age 14 to 65 years, male or female. Underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of acute graft-versus-host disease (aGVHD) according to standard criteria, with gastrointestinal involvement (e.g., abdominal pain and diarrhea), and classified as grade II-IV.

Steroid-refractory or steroid-dependent aGVHD, defined as:

Disease progression within 3 days of systemic corticosteroid treatment, or No response within 7 days, or Failure to achieve complete response after 28 days of immunosuppressive therapy, or Recurrence or worsening during steroid tapering. Absolute neutrophil count ≥ 0.5 × 10⁹/L for at least 3 consecutive days. Traditional Chinese medicine (TCM) syndrome differentiation consistent with spleen-kidney yang deficiency.

Female participants of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study.

Male participants must agree to use effective contraception during the study. Ability to understand and willingness to sign a written informed consent form. Willingness and ability to comply with study procedures and follow-up.

Exclusion Criteria:

• Participants meeting any of the following criteria will be excluded:

Prior treatment with ≥1 systemic therapy for aGVHD other than corticosteroids. Diagnosis of GVHD overlap syndrome according to NIH criteria. History of splenectomy after transplantation. Evidence of relapse of the underlying disease or receipt of anti-relapse therapy after transplantation.

Unresolved toxicities or complications from prior transplantation (excluding GVHD).

Prior moxibustion therapy after transplantation. Uncontrolled active infection. Known human immunodeficiency virus (HIV) infection. Active hepatitis B or C infection requiring treatment, or risk of HBV reactivation.

Receipt of other investigational therapy within 21 days prior to enrollment (or within 5 half-lives, whichever is longer).

Renal dysfunction: serum creatinine ≥ 2.0 mg/dL or creatinine clearance < 40 mL/min.

Hepatic dysfunction unrelated to GVHD, including cholestatic disease or unresolved hepatic veno-occlusive disease.

Severe cardiovascular disease, including unstable angina, myocardial infarction within 6 months, NYHA class III-IV heart failure, or circulatory failure requiring vasoactive support.

Severe respiratory disease requiring mechanical ventilation or ≥50% oxygen support.

Use of high-dose corticosteroids (≥1 mg/kg/day methylprednisolone or equivalent) for non-GVHD indications within 7 days prior to enrollment.

Pregnant or breastfeeding women. Severe skin damage or known allergy/intolerance to study-related procedures. Any other condition that, in the investigator's judgment, would interfere with study participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Moxibustion Once Daily Plus Best Available Treatment (QD Group)	Procedure: Moxibustion; Moxibustion applied at Tianshu (ST25), Shenque (CV8), and Qihai (CV6), 30 minutes once daily for 28 days.
Experimental: Moxibustion Twice Daily Plus Best Available Treatment (BID Group)	Procedure: Moxibustion Twice Daily Plus Best Available Treatment (BID Group); Moxibustion applied at Tianshu (ST25), Shenque (CV8), and Qihai (CV6), 30 minutes twice daily for 28 days.; Drug: Best Available Treatment (BAT); Investigator-selected second-line therapy for SR-aGVHD, including ruxolitinib, basiliximab, or methotrexate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR) at Day 28	Overall response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) according to established criteria for acute graft-versus-host disease.	Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Durable Overall Response Rate (ORR) at Day 56		Day 56
Incidence and Severity of Chronic Graft-Versus-Host Disease (cGVHD)	Incidence and severity of chronic GVHD assessed according to standard clinical criteria.	Up to 180 days
Non-Relapse Mortality (NRM)	Death without prior relapse of the underlying disease.	Up to 180 days
Overall Survival (OS)	Time from enrollment to death from any cause.	Up to 180 days
Traditional Chinese Medicine (TCM) Syndrome Score	Changes in TCM syndrome scores based on predefined criteria for spleen-kidney yang deficiency.	Baseline, Day 14, Day 28, Day 56, Day 90, Day 180

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events (AEs)	Incidence and severity of adverse events assessed according to CTCAE version 5.0.	From baseline to 180 days

Collaborators and Investigators

• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: May 3, 2026
• First Submitted That Met QC Criteria: May 3, 2026
• First Posted (Actual): May 7, 2026

Study Record Updates

• Last Update Posted (Actual): May 7, 2026
• Last Update Submitted That Met QC Criteria: May 3, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Graft vs Host Disease; Therapeutics; Complementary Therapies; Acupuncture Therapy; Moxibustion
• Other Study ID Numbers: [2025]num(0924)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No